Research peptides and the law

The federal starting point: what makes something a "drug"

Under the Food, Drug & Cosmetic Act (FDCA), whether a substance is legally a "drug" subject to FDA approval requirements does not turn solely on chemistry — it turns substantially on intended use. FDA's intended-use regulation, 21 CFR 201.128, defines intended use by "the objective intent of the persons legally responsible for the labeling," which can be shown by their own statements, by the product's design, or by the circumstances of how it is distributed and sold. A label that says "research use only" is evidence of intent, but it is not the only evidence, and it does not automatically control if everything else about the sale points the other way.

Selling a peptide genuinely intended for and marketed to laboratories is a different legal act from selling the same peptide with website copy, dosing charts, and customer reviews aimed at people injecting it into themselves. Both scenarios can use the exact same "research use only" label. The label is not the thing the law looks at first.

What FDA enforcement has actually looked like

This is not a hypothetical framework — the FDA has applied it repeatedly. A February 2025 warning letter to a peptide seller stated that despite "research use only," "not for human consumption," and "lab purposes only" language on its labeling, evidence from the company's own website established that its semaglutide and tirzepatide products were drugs intended for human use (FDA warning letter). In September 2025, the FDA sent more than 50 warning letters to online sellers, telehealth providers, and compounding entities marketing GLP-1 products, citing unapproved-drug and misleading-advertising violations (Wilson Sonsini summary). More letters followed into 2026, targeting sellers of other research-labeled peptides on the same "research use only" theory (example, example).

What this does and doesn't establish: every published letter we found was addressed to a seller — a company introducing a product into interstate commerce — not to an individual buyer or user. That is a meaningful distinction. It does not mean an individual buyer or user faces zero legal exposure of any kind; it means the enforcement record we can point to is specifically about the sale, not about possession or personal use. We were not able to verify a published FDA or DOJ action against an individual purchaser for personal-use possession of a research-labeled peptide, and this page will not assert one exists.

Not a scheduled substance — a different framework entirely

It's worth separating this clearly from drug scheduling. Most peptides discussed in this space are not listed on the DEA's controlled substance schedules the way, say, an opioid or a stimulant would be. The legal exposure discussed above runs through the FDCA's unapproved-drug and misbranding provisions, a civil and administrative enforcement framework aimed primarily at commercial actors, not the criminal controlled-substances framework most people associate with "illegal drugs." That distinction matters and is frequently blurred in vendor marketing on both sides — some sellers imply zero legal risk exists at all because nothing is "scheduled"; that is an overstatement of what the FDCA framework above actually says.

Why this varies by state

Compounding itself is regulated substantially at the state level — state boards of pharmacy license and discipline pharmacists and, in some cases, prescribing clinicians, independent of what the FDA does federally. That means a compound's practical accessibility can differ meaningfully between states even where the federal picture is identical, because a state board can take licensing action against a clinician's practice under state law, on a separate timeline and separate standard from any federal FDA action. We were not able to verify specific, citable examples of individual state board actions strong enough to generalize into a state-by-state map, and a page that confidently presented one would likely be wrong somewhere by the time you read it. If a state-specific answer matters to you, your state's board of pharmacy or board of medicine is the primary source, not this page.

Why the picture keeps changing

This is not a settled area, and treating any snapshot as permanent is a mistake. In just the past year: the FDA removed a wave of substances from its "Category 2" list in April 2026, that removal moved into formal Pharmacy Compounding Advisory Committee review scheduled for July 2026, the semaglutide shortage that had permitted broader compounding was declared resolved in early 2025 with compounders given until spring 2025 to stop (FDA declaratory order), and warning-letter waves have continued into 2026. A page written a year ago about "the legal status of peptides" would already be out of date in several specific ways. Treat this one the same way: check the date above, and check primary sources for anything time-sensitive.

Where to look for a real answer

• FDA warning letters database — the primary record of enforcement actions and their stated legal basis.
• 21 CFR 201.128 — the federal intended-use regulation discussed above, in full.
• FDA's 503A bulk drug substances page — the current compounding-eligibility list, which changes.
• Your state's board of pharmacy and board of medicine — for anything specific to where you are.
• An attorney licensed in your state — for anything you need to actually rely on.

Related reading

• What 503A, 503B, and research-only actually mean.
• The FDA-approved peptides list, by status.
• All guides.